First human test of BIIB145 begins: could this be a new MS hope?
NCT ID NCT07225517
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests the safety of a new drug called BIIB145, designed to help people with multiple sclerosis (MS). Researchers will give the drug or a placebo to 104 healthy adults in three parts, checking for side effects and how the body processes it. The goal is to see if it's safe enough to test in MS patients later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BIIB145
- What this could lead to
- If this drug is safe and works well, it could lead to a new treatment for multiple sclerosis (MS).
- What could go wrong
- This is a very early Phase 1 study in healthy people, not MS patients. The drug may not be safe or effective in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PPD Austin Clinic
RECRUITINGAustin, Texas, 78744, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?